


LIVER CANCER

FACTS AND FIGURES

SYMPTOMS INCLUDE¹

- LOSS OF APPETITE
- NAUSEA AND VOMITING
- UPPER ABDOMINAL PAIN
- ABDOMINAL SWELLING
- JAUNDICE
- GENERALIZED WEAKNESS
- UNINTENTIONAL WEIGHT LOSS




Primary liver cancer is the 3rd leading cause of cancer death globally²



COVID-19

Exacerbation of existing chronic liver disease and complicated management of cancer in most HCC patients⁵

Worldwide, ~905,677 people were diagnosed and ~830,180 people died due to primary liver cancer in 2020²



The number of new cases and deaths are predicted to rise by >50% between 2020-2040⁶

HCC accounts for 90% of primary liver cancer³



Shift in predominant risk factors, with a decrease in HBV and HCV infections and an increase in obesity and diabetes²

RISK FACTORS^{1,4}




- Chronic infection with HBV/ HCV
- Cirrhosis
- Non-alcoholic fatty liver disease
- Certain inherited liver disorders
- Excessive alcohol consumption
- Diabetes
- Exposure to aflatoxins



In most regions, men have 2 to 3 times higher incidence and mortality rates than women²

HCC treatment market⁷




\$106.48 M
Market size growth



CAGR of 4.1%

Estimated age-standardized liver cancer incidence rates per 100,000 people 2020⁸



<3.4
3.3-4.5

4.5-5.8
5.8-8.5

>8.5
Data not available

* HCC – Hepatocellular carcinoma
HBV – Hepatitis B virus
HCV – Hepatitis C virus
CAGR – Compound annual growth rate

Disclaimer:
This publication on the liver cancer pathway framework was updated on 22.05.2023. It cannot be taken as a recommendation for the readers, especially not as a guideline for treatment, and it is not a medical document. There is no guarantee for completeness or global correctness, the various pain points, solutions, and statistical data are examples only. Sources are multiple, such as public statistics, expert opinions, open innovation workshops, research, own data and many more (see references).
The products and features mentioned may not be available in all countries and their future availability cannot be guaranteed. Some products mentioned are planned and under development.

1. Mayo Foundation for Medical Education and Research (MFMER). (2021, May 18). Liver cancer symptoms causes. Mayo Clinic. Retrieved October 05, 2022, from <https://www.mayoclinic.org/diseases-conditions/liver-cancer/symptoms-causes/syc-20353659>
2. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71(3), 209-249.
3. Kim E. & Viatour P. (2020, December). Hepatocellular carcinoma: old friends and new tricks. Experimental & Molecular Medicine, 52(12), 1898-1907. <https://doi.org/10.1038/s12276-020-00527-1>
4. Llovet J.M., Kelley R.K. & Villanueva A. et al. (2021, January 21). Hepatocellular carcinoma. Nature reviews disease primers, 6. <https://doi.org/10.1038/s41572-020-00240-3>
5. Chan S.L. & Kudo M. (2022). Impacts of COVID-19 on Liver Cancers: During and after the Pandemic. Liver Cancer, 9(5), 491-502. <https://doi.org/10.1159/000510765>
6. Runggay, H., Arnold, M., Ferlay, J., Lesi, O., Cabasag, C. J., Vignat, J., Laversanne, M., McGlynn, K. A., & Soerjomataram, I. (2022). Global burden of primary liver cancer in 2020 and predictions to 2040. Journal of hepatology, 77(6), 1598-1606. <https://doi.org/10.1016/j.jhep.2022.08.021>
7. Technavio Plus. (2021, February). Report/hepatocellular-carcinoma-drugs-market-industry-analysis. Technavio. Retrieved October 05, 2022, from <https://www.technavio.com/report/hepatocellular-carcinoma-drugs-market-industry-analysis>
8. World Health Organization. (n.d.). Cancer Today . Global Cancer Observatory - International Agency for Research on Cancer. Retrieved March 7, 2023, from <https://gco.iarc.fr/today/online-analysis-map>

